Shares of Capricor Therapeutics Inc (NASDAQ:CAPR) bought by Bank of New York Mellon Corp

Bank of New York Mellon Corp boosted its stake in Capricor Therapeutics Inc (NASDAQ:CAPR – Free Report) by 12.8% during the second quarter, Holdings Channel.com reports. The institutional investor owned 79,782 shares of the biotechnology company’s stock after acquiring an additional 9,040 shares during the quarter. Bank of New York Mellon Corp’s holdings in Capricor Therapeutics were worth $381,000 as of its most recent SEC filing.

Separately, Vanguard Group Inc. boosted its holdings in Capricor Therapeutics by 17.2% in the first quarter. Vanguard Group Inc. now owns 1,365,903 shares of the biotechnology company’s stock worth $9,274,000 after acquiring an additional 200,499 shares during the period. 21.68% of shares are currently owned by institutional investors.

Analysts set new price targets

A number of analysts have recently issued reports on the stock. Maxim Group raised their price objective on shares of Capricor Therapeutics from $12.00 to $25.00 and gave the company a “buy” rating in a research note on Wednesday. Oppenheimer reiterated an “outperform” rating and issued a $15.00 price objective on shares of Capricor Therapeutics in a report on Monday. Cantor Fitzgerald restated an “overweight” rating and set a $8.00 target price on shares of Capricor Therapeutics in a research note on Friday, September 20th. Finally, HC Wainwright reiterated a “buy” rating and issued a $40.00 target price on shares of Capricor Therapeutics in a research note on Tuesday. One equities research analyst has rated the stock with a sell rating and five have given a buy rating to the company. The company presently has an average rating of “Moderate Buy” and a consensus price target of $22.60, based on data from MarketBeat.com.

Get the latest analysis on Capricor Therapeutics

Insider Trading at Capricor Therapeutics

In other news, major shareholder Shinyaku Co Ltd Nippon acquired 2,798,507 shares of Capricor Therapeutics stock in a transaction that occurred on Friday, September 20th. The shares were acquired at an average cost of $5.36 per share, for a total transaction of $14,999,997.52. Following the completion of the purchase, the insider now directly owns 7,090,351 shares of the company’s stock, valued at approximately $38,004,281.36. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible via this hyperlink. Insiders own 12.00% of the company’s shares.

Capricor Therapeutics price performance

NASDAQ CAPR opened at $10.34 on Thursday. The company has a market cap of $336.46 million, a price-to-earnings ratio of -11.88 and a beta of 3.92. Capricor Therapeutics Inc has a 12-month low of $2.68 and a 12-month high of $12.87. The company’s fifty day moving average price is $4.59 and its two hundred day moving average price is $5.25.

Capricor Therapeutics (NASDAQ:CAPR – Get Free Report ) last posted its quarterly earnings results on Wednesday, August 7th. The biotechnology company reported ($0.35) EPS for the quarter, missing the consensus estimate of ($0.32) by ($0.03). The company had revenue of $3.97 million for the quarter, compared to the consensus estimate of $4.51 million. Capricor Therapeutics had a negative return on equity of 220.27% and a negative net margin of 102.93%. As a group, analysts anticipate that Capricor Therapeutics Inc will post -1.14 EPS for the current year.

Capricor Therapeutics Company Profile

(Free Report)

Capricor Therapeutics, Inc (NASDAQ:CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapies for the treatment of rare disorders. Capricor’s lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy.

See Also

Want to see what other hedge funds own CAPR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Capricor Therapeutics Inc (NASDAQ:CAPR – Free Report).

Receive daily news and ratings for Capricor Therapeutics – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Capricor Therapeutics and related companies with MarketBeat.com ‘s FREE daily email newsletter.